Security key
12529R107
C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CCCC)
CUSIP: 12529R107
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 52,538,995
- Total 13F value
- $116,636,299
- Share change
- -2,025,201
- Put/Call ratio
- 56%
- SEC-reported price per share
- $2.22
- Number of holders
- 96
- Value change
- -$3,450,925
- Number of buys
- 47
- Number of sells
- 62
- Shares outstanding
- 111,000,000
Holder snapshot
7 signals
Show 1 more signal
Security identity
1 source field
Report period
Q3 2025
Institutions
96
Top holders
10
CCCC full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
C4 Therapeutics, Inc. SEC filings
C4 Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 12529R107
Recent filing periods:
Ownership snapshot
Top reported holders of CCCC - C4 Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
WASATCH ADVISORS LP
Disclosed value leader
WASATCH ADVISORS LP
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 6.8%
13D/G row: WASATCH ADVISORS LP
Showing 1-6 of 15 holder rows.
Quick read
WASATCH ADVISORS LP leads the comparable SEC ownership view at 6.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
WASATCH ADVISORS LP
6.8%
BlackRock, Inc.
2.5%
Lynx1 Capital Management LP
6.4%
Soleus Capital Management, L.P.
6.3%
ORBIMED ADVISORS LLC
6.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| WASATCH ADVISORS LP |
13D/G
13F
Company
|
6.8%
|
$10,773,085
4,852,741 shares
|
-$5,817,712 | 30 Sep 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
2.5%
from 13D/G
|
$2,614,919
1,828,614 shares
|
— | 30 Jun 2025 |
| Lynx1 Capital Management LP |
13F
Company
|
6.4%
|
$10,150,330
7,098,133 shares
|
— | 30 Jun 2025 |
| Soleus Capital Management, L.P. |
13F
Company
|
6.3%
|
$9,979,887
6,978,942 shares
|
— | 30 Jun 2025 |
| ORBIMED ADVISORS LLC |
13F
Company
|
6.2%
|
$9,767,329
6,830,300 shares
|
— | 30 Jun 2025 |
| MORGAN STANLEY |
13F
Company
|
4.3%
|
$6,798,489
4,754,188 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
96
Shares
52,538,995
Rows available
96
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
102
Q3 2025 holders
96
Holder diff
-6
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend